Sexual Rehabilitation After Therapy for Localized Disease

  • Milton M. Lakin
  • Leslie R. Schover
Part of the Current Clinical Urology book series (CCU)


Sexual rehabilitation is not a process that begins only after treatment for localized prostate cancer. Men and their partners need some understanding of the sexual consequences of cancer treatment in order to make an informed choice about cancer therapy. Not only have such organizations as the American Cancer Society, the National Prostate Cancer Coalition, and the American Foundation for Urological Diseases worked to increase the public’s knowledge about prostate cancer and recommendations for screening, but they also have encouraged men to participate actively in decision making about their cancer treatment. Compared to just 10 years ago, men now have dozens of books, internet websites, and pamphlets available giving advice on choosing an effective treatment and avoiding complications, such as sexual dysfunction. Many men are aware of publicity about the limited data showing effectiveness of aggressive treatment for prostate cancer, and the advocacy by some physician groups of reduced use of screening and increased use of watchful waiting as a treatment option (1).


Prostate Cancer Erectile Dysfunction Radical Prostatectomy Sexual Function Sexual Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Coley CM, Barry MJ, Mulley AG, for the Health and Public Policy Committee of the American College of Physician. Position paper: clinical guidline: Part III: Screening for prostate cancer. Ann Int Med 1997; 126: 480–484.Google Scholar
  2. 2.
    Mazur DJ, Merz JF. Older patients’ willingness to trade off urologic adverse outcomes for a better chance at five-year survival in the clinical setting of prostate cancer. J Am Geriat Soc 1995; 43: 979–984.PubMedGoogle Scholar
  3. 3.
    Talcott JA. Quality of life in early prostate cancer; Do we know enough to treat? Hematol Oncol Clin North Am 1996; 10 (3): 691–701.PubMedCrossRefGoogle Scholar
  4. 4.
    Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for early prostate cancer. JAMA 1995; 273: 129–134.PubMedCrossRefGoogle Scholar
  5. 5.
    Beard CJ, Propert KJ, Rieker PP, Clark JA, Kaplan I, Kantoff PW, et al. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. J Clin Oncol 1997; 15: 223–229.PubMedGoogle Scholar
  6. 6.
    Braslis KG, Santa-Cruz C, Brickman AL, Soloway MS. Quality of life 12 months after radical prostatectomy. Br J Urol 1995; 75: 48–53.PubMedCrossRefGoogle Scholar
  7. 7.
    Fossa SD, Woehre H, Kurth KH, Hetherington J, Bakke H, Tustad DA, Skanvik R. Influence of uro-logical morbidity on quality of life in patients with prostate cancer. Eur Urol 1997; 31 (Suppl 3): 3–8.PubMedGoogle Scholar
  8. 8.
    Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: A study of medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 1996; 14: 2258–2265.PubMedGoogle Scholar
  9. 9.
    Schrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL. Quality of life and treatment outcomes: Prostate carcinoma patients’ perspectives after prostatectomy or radiation therapy. Cancer 1997; 79: 1977–1986.CrossRefGoogle Scholar
  10. 10.
    Beckendorf V, Hay M, Rozan R, Lagrange JL, N’Guyen T, Giraud B. Changes in sexual function after radiotherapy treatment of prostate cancer. Br J Urol 1996; 77: 118–123.PubMedCrossRefGoogle Scholar
  11. 11.
    Fransson P, Widmark A. Self-assessed sexual function after pelvic irradiation for prostate carcinoma: Comparison with an age-matched control group. Cancer 1996; 78: 1066–1078.PubMedCrossRefGoogle Scholar
  12. 12.
    Talcott JA, Rieker P, Propert KJ, Clark JA, Wishnow KI, Loughlin KR, et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 1997; 89: 1117–1123.PubMedCrossRefGoogle Scholar
  13. 13.
    Robinson JW, Dufour MS, Fung TS. Erectile functioning of men treated for prostate carcinoma. Cancer 1997; 79: 538–544.PubMedCrossRefGoogle Scholar
  14. 14.
    Mantz CA, Song P, Farhangi E, Nautiyal J, Awan A, Ignacio L, et al. Potency probability following conformal megavoltage radiotherapy suing conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 551–557.PubMedCrossRefGoogle Scholar
  15. 15.
    Roach M III, Chinn DM, Holland J, Clarke M. A pilot survey of sexual function and quality of life following 3D conformal radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1996; 35: 869–874.PubMedCrossRefGoogle Scholar
  16. 16.
    Stock RG, Stone NN, Iannuzzi C. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996; 35: 267–272.PubMedCrossRefGoogle Scholar
  17. 17.
    Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996; 14: 449–453.PubMedGoogle Scholar
  18. 18.
    Chaikin DC, Broderick GA, Malloy TR, Malkowicz SB, Whittington R, Wein AJ. Erectile dysfunctionfollowing minimally invasive treatments for prostate cancer. Urology 1996; 48: 100–104.PubMedCrossRefGoogle Scholar
  19. 19.
    Geary ES, Dendinger TE, Freiha FS, Stamey TA. Nerve sparing radical prostatectomy: a different view. J Urol 1995; 154: 145–149.PubMedCrossRefGoogle Scholar
  20. 20.
    Jonler M, Ritter MA, Brinkmann R, Messing EM, Rhodes PR, Bruskewitz RD. Sequelae of definitive radiation therapy for prostate cancer localized in the pelvis. Urology 1994; 44: 876–872.PubMedCrossRefGoogle Scholar
  21. 21.
    Ojdeby G, Claezon A, Brekkan E, Haggman M, Norlen BJ. Urinary incontinence and sexual impotence after radical prostatectomy. Scand J Urol Nephrol 1996; 30: 473–477.PubMedCrossRefGoogle Scholar
  22. 22.
    Helgason AR, Adolfsson J, Dickman P, Arver S, Fredrikson M, Steineck G. Factors associated with waning sexual function among elderly men and prostate cancer patients. J Urol 1997; 158: 155–159.PubMedCrossRefGoogle Scholar
  23. 23.
    Aboseif S, Shinohara K, Borirakchanyavat S, Deirmenjian J, Carroll PR. The effect of cryosurgical ablation of the prostate on erectile function. Br J Urol 1997; 80: 918–922.PubMedCrossRefGoogle Scholar
  24. 24.
    Slag MF, Morley JE, Elson MK, Trence DL, Nelson CJ, Nelson AE, et al. Impotence in medical clinic outpatients. JAMA 1983; 249: 1736–1740.PubMedCrossRefGoogle Scholar
  25. 25.
    Perez ED, Mulligan T, Wan T. Why men are interested in an evaluation for a sexual problem. J Am Geriat Soc 1993; 41: 233–237.PubMedGoogle Scholar
  26. 26.
    Solstad K, Hertoft P. Frequency of sexual problems and sexual dysfunction in middle-aged Danish men. Arch Sex Behav 1993; 22: 51–58.PubMedCrossRefGoogle Scholar
  27. 27.
    Schover LR, Evans RB, von Eschenbach AC. Sexual rehabilitation in a cancer center: Diagnosis and outcome in 384 consultations. Arch Sex Behav 1987; 16: 445–461.PubMedCrossRefGoogle Scholar
  28. 28.
    Schover LR. Sexual rehabilitation after treatment for prostate cancer. Cancer 1993; 71 (Suppl): 1024–1030.PubMedCrossRefGoogle Scholar
  29. 29.
    Schover LR. Sexuality and Fertility After Cancer. John Wiley, New York, 1997.Google Scholar
  30. 30.
    Schover LR, Evans RB, von Eschenbach AC. Sexual rehabilitation and male radical cystectomy. J Urol 1986; 136: 1015–1017.PubMedGoogle Scholar
  31. 31.
    Schover LR. Sexuality and Cancer: For the Man Who Has Cancer and His Partner. American Cancer Society, New York, (booklet 4658), rev., 1995.Google Scholar
  32. 32.
    Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial. J Urol 1997; 158: 1408–1410.PubMedCrossRefGoogle Scholar
  33. 33.
    Lakin MM, Chen RN, Llorens SA, et al. Prostaglandin El injection therapy for prost-prostatectomy impotence: An outcome analysis. J Urol 1996; 155 (Suppl): 639.CrossRefGoogle Scholar
  34. 34.
    Zorgniotti AW, LeFleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 1985; 133: 339–341.Google Scholar
  35. 35.
    Soderdahl DW, Knight RW, Hansberry KL. Erectile dysfunction following transurethral resection of the prostate. J Urol 1996; 156: 1354–1356.PubMedCrossRefGoogle Scholar
  36. 36.
    Padma-Nathan H. Minimally invasive therapy for erectile dysfunction: intracavernosal, oral, transdermal/transglanular and intraurethral approaches. In: Mulcahy JJ, ed. Diagnosis and Management of Male Sexual Dysfunction. Igaku-Shoin, New York, 1997, pp. 182–195.Google Scholar
  37. 37.
    Aboseif S, Shinohara K, Breza J, Benard F, Narayan P. Role of penile vascular injury in erectile dysfunction after radical prostatectomy. Br J Urol 1994; 73: 75–82.PubMedCrossRefGoogle Scholar
  38. 38.
    Goldstein I, Feldman MU, Deckers PJ, et al. Radiation-associated impotence. A clinical study of it’s mechanism. JAMA 1984; 251: 903–910.PubMedCrossRefGoogle Scholar
  39. 39.
    Lakin MM, Montague DK. Non-surgical therapeutic alternatives for impotence. In: Hashmat Aizid I, Das S, eds. The Penis. Lea and Febiger, Philadelphia, 1993, pp. 154–173.Google Scholar
  40. 40.
    Khasar SG, Ho T, Green PG, Levine JD. Comparison of prostaglandin E1 and prostaglandin E2-induced hyperalgesia in the rat. Neuroscience 1994; 62 (2): 345–350.PubMedCrossRefGoogle Scholar
  41. 41.
    Porst H. The rationale for PGE1 in erectile failure: a survey of wordwide experience. J Urol 1996; 155: 802–815.PubMedCrossRefGoogle Scholar
  42. 42.
    Aboseif SR, Breza J, Ruud JL, Bosch H, Benard F, Stief CG, et al. Local and systemic effects of chronic intracavernous injection of papaverine, PGE1, and saline in primates. J Urol 1989; 142: 403–408.PubMedGoogle Scholar
  43. 43.
    Moreland RB, Abdulmaged T, Mc Millin MA, Smith B, Goldstein I, Saenz De Tejada I. PGE1 suppresses the induction of collagen synthesis by transforming growth factor beta 1 in human corpus cavernosum smooth muscle. J Urol 1995; 153: 826–834.PubMedCrossRefGoogle Scholar
  44. 44.
    Sexton WJ, Benedict JS, Jarow JP. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy. J Urol 1998; 159: 811–815.PubMedCrossRefGoogle Scholar
  45. 45.
    Padma-Nathan H, Hellstrom WJG, Kaiser FE, Labasky RF, Lue TF. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336 (1): 1–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Costabile RA, Govier FE, Ferrigni RG, McVary KT, Shabsigh R, Nemo KJ, et al. Safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1997; 157 (4): 1424.Google Scholar
  47. 47.
    Paolone DR, Lakin MM, Ingleright BJ, Angermeier KW, Montague DK. Intraurethral Alprostadil Therapy at The Cleveland Clinic Foundation. Abstract submitted to North Central Section AUA for presentation in October, 1998.Google Scholar
  48. 48.
    Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338 (20): 1397–1404.PubMedCrossRefGoogle Scholar
  49. 49.
    Schover LR, Montague DK, Lakin MM. Supportive care and the quality of life of the cancer patient: sexual problems. In: Cancer: Principles and Practice of Oncology, 5th ed. De Vita JT, Hellman S, Rosenberg SA, eds. Lippincott, Philadelphia, 1997, pp. 2857–2872.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2000

Authors and Affiliations

  • Milton M. Lakin
  • Leslie R. Schover

There are no affiliations available

Personalised recommendations